Sajkowski Daniel J 4
4 · Calumet, Inc. /DE · Filed Feb 26, 2026
Research Summary
AI-generated summary of this filing
Calumet (CLMT) Director Daniel J. Sajkowski Sells Shares
What Happened Daniel J. Sajkowski, a director of Calumet, Inc. (CLMT), sold a total of 82,000 shares in five open‑market disposals between March and July 2025. The transactions were for: 20,000 shares on 2025-03-03 at a weighted avg $13.73 ($274,600); 20,000 on 2025-04-01 at $12.55 ($251,000); 20,000 on 2025-05-01 at $10.66 ($213,200); 20,000 on 2025-06-02 at $13.40 ($268,000); and 2,000 on 2025-07-01 at $15.77 ($31,540). Total proceeds across these sales were roughly $1.038 million. These were sales (not purchases) and were effected pursuant to a pre-established trading plan.
Key Details
- Transaction dates & amounts:
- 2025-03-03: 20,000 shares @ weighted avg $13.73 — $274,600 (F2: price range $13.35–$14.06)
- 2025-04-01: 20,000 shares @ weighted avg $12.55 — $251,000 (F3: $12.06–$12.91)
- 2025-05-01: 20,000 shares @ weighted avg $10.66 — $213,200 (F4: $10.40–$10.90)
- 2025-06-02: 20,000 shares @ weighted avg $13.40 — $268,000 (F5: $13.07–$13.86)
- 2025-07-01: 2,000 shares @ weighted avg $15.77 — $31,540 (F6: $15.53–$16.02)
- Shares owned after the transactions: Not specified in the material provided in this summary (see the Form 4 for reported holdings).
- Notable footnotes:
- Sales were effected under a Rule 10b5-1 trading plan adopted March 14, 2024 (F1).
- Several reported prices are weighted averages; the filing discloses price ranges and offers to provide per‑trade breakdown on request (F2–F6).
- The filing notes Calumet became successor issuer to Calumet Specialty Products Partners on July 10, 2024 (unit-to-share conversion).
- Filing timeliness: The Form 4 was filed on 2026-02-26 for transactions in 2025 (period of report 2025-03-03), which is later than the typical two-business-day SEC reporting window for insider trades.
Context
- Because these sales were made under a pre-established Rule 10b5-1 plan, they are scheduled transactions and are generally considered routine rather than a direct, contemporaneous signal of the insider’s view of the company. For retail investors, scheduled sales reduce the informational value compared with discretionary, same‑day insider sales.
Insider Transaction Report
Form 4
Sajkowski Daniel J
Director
Transactions
- Sale
Common Stock, par value $0.01 per share
[F1][F2]2025-03-03$13.73/sh−20,000$274,600→ 141,959 total - Sale
Common Stock, par value $0.01 per share
[F1][F3]2025-04-01$12.55/sh−20,000$251,000→ 121,959 total - Sale
Common Stock, par value $0.01 per share
[F1][F4]2025-05-01$10.66/sh−20,000$213,200→ 101,959 total - Sale
Common Stock, par value $0.01 per share
[F1][F5]2025-06-02$13.40/sh−20,000$268,000→ 81,959 total - Sale
Common Stock, par value $0.01 per share
[F1][F6]2025-07-01$15.77/sh−2,000$31,540→ 82,237 total
Footnotes (6)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2024. The closing price of one common unit of Calumet Specialty Products Partners, L.P., (the "Partnership") as reported on the Nasdaq Global Select Market, on the date the Rule 10b5-1 trading plan was adopted by the reporting person was $14.25 per unit. On July 10, 2024, Calumet, Inc. became the successor issuer to, and parent holding company of, the Partnership pursuant to a conversion transaction in which all of the Partnership's outstanding common units representing limited partner interests were automatically exchanged into an equal number of shares of Calumet, Inc. common stock.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.35 per share to $14.06 per share. The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- [F3]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.06 per share to $12.91 per share. The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
- [F4]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.40 per share to $10.90 per share. The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4.
- [F5]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.07 per share to $13.86 per share. The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) to this Form 4.
- [F6]The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.53 per share to $16.02 per share. The reporting person undertakes to provide to Calumet, Inc., any security holder of Calumet, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (6) to this Form 4.
Signature
/s/ Connor J. Egan, as attorney-in-fact|2026-02-26